Autologous Hematopoietic Cell Transplantation in Diffuse Large B-cell Lymphoma After Three or More Lines of Prior Therapy: Evidence of Durable Benefit

Overview

Journal Haematologica

Specialty Hematology

Date 2022 Feb 3

PMID 35112554

Authors

Matthew Mei

Mehdi Hamadani

Kwang W Ahn

Yue Chen

Mohamed A Kharfan-Dabaja

Craig Sauter

Alex F Herrera

Affiliations

Soon will be listed here.

Citing Articles

Clinical outcomes in transplant-eligible patients with relapsed or refractory diffuse large B-cell lymphoma after second-line salvage chemotherapy: A retrospective study.

Yagi Y, Kanemasa Y, Sasaki Y, Sei M, Matsuo T, Ishimine K Cancer Med. 2023; 12(17):17808-17821.

PMID: 37635630 PMC: 10523963. DOI: 10.1002/cam4.6412.

The role of CAR-T cell therapy as second line in diffuse large B-cell lymphoma.

Albanyan O, Chavez J, Munoz J Ther Adv Hematol. 2022; 13:20406207221141511.

PMID: 36505886 PMC: 9730015. DOI: 10.1177/20406207221141511.

Minimal residual disease in patients with diffuse large B-cell lymphoma undergoing autologous stem cell transplantation.

Merryman R, Redd R, Taranto E, Ahmed G, Jeter E, McHugh K Blood Adv. 2022; 7(17):4748-4759.

PMID: 36399518 PMC: 10468363. DOI: 10.1182/bloodadvances.2022007706.

Cost-effectiveness of second-line axicabtagene ciloleucel in relapsed refractory diffuse large B-cell lymphoma.

Kambhampati S, Saumoy M, Schneider Y, Serrao S, Solaimani P, Budde L Blood. 2022; 140(19):2024-2036.

PMID: 35914220 PMC: 9837443. DOI: 10.1182/blood.2022016747.

Stem cell transplant for lymphoma - never too late?.

Cashen A, Bartlett N Haematologica. 2022; 107(5):1024-1025.

PMID: 35112557 PMC: 9052924. DOI: 10.3324/haematol.2021.280519.

References

Crump M, Neelapu S, Farooq U, Van den Neste E, Kuruvilla J, Westin J . Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017; 130(16):1800-1808. PMC: 5649550. DOI: 10.1182/blood-2017-03-769620. View

Abramson J, Palomba M, Gordon L, Lunning M, Wang M, Arnason J . Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020; 396(10254):839-852. DOI: 10.1016/S0140-6736(20)31366-0. View

Van Den Neste E, Schmitz N, Mounier N, Gill D, Linch D, Trneny M . Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the International CORAL study. Bone Marrow Transplant. 2015; 51(1):51-7. DOI: 10.1038/bmt.2015.213. View

Kansagra A, Farnia S, Majhail N . Expanding Access to Chimeric Antigen Receptor T-Cell Therapies: Challenges and Opportunities. Am Soc Clin Oncol Educ Book. 2020; 40:1-8. DOI: 10.1200/EDBK_279151. View

Gisselbrecht C, Glass B, Mounier N, Singh Gill D, Linch D, Trneny M . Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol. 2010; 28(27):4184-90. PMC: 3664033. DOI: 10.1200/JCO.2010.28.1618. View

Philip T, Guglielmi C, Hagenbeek A, Somers R, van der Lelie H, Bron D . Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med. 1995; 333(23):1540-5. DOI: 10.1056/NEJM199512073332305. View

Commenges D, Andersen P . Score test of homogeneity for survival data. Lifetime Data Anal. 1995; 1(2):145-56; discussion 157-9. DOI: 10.1007/BF00985764. View

Jagadeesh D, Majhail N, He Y, Ahn K, Litovich C, Ahmed S . Outcomes of rituximab-BEAM versus BEAM conditioning regimen in patients with diffuse large B cell lymphoma undergoing autologous transplantation. Cancer. 2020; 126(10):2279-2287. PMC: 7190439. DOI: 10.1002/cncr.32752. View

Neelapu S, Locke F, Bartlett N, Lekakis L, Miklos D, Jacobson C . Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. N Engl J Med. 2017; 377(26):2531-2544. PMC: 5882485. DOI: 10.1056/NEJMoa1707447. View

10.

Burki T . CAR T-cell therapy roll-out in low-income and middle-income countries. Lancet Haematol. 2021; 8(4):e252-e253. DOI: 10.1016/S2352-3026(21)00068-5. View

11.

Cheson B, Fisher R, Barrington S, Cavalli F, Schwartz L, Zucca E . Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014; 32(27):3059-68. PMC: 4979083. DOI: 10.1200/JCO.2013.54.8800. View

12.

Cheson B, Pfistner B, Juweid M, Gascoyne R, Specht L, Horning S . Revised response criteria for malignant lymphoma. J Clin Oncol. 2007; 25(5):579-86. DOI: 10.1200/JCO.2006.09.2403. View

13.

Hamadani M, Hari P, Zhang Y, Carreras J, Akpek G, Aljurf M . Early failure of frontline rituximab-containing chemo-immunotherapy in diffuse large B cell lymphoma does not predict futility of autologous hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2014; 20(11):1729-36. PMC: 4194275. DOI: 10.1016/j.bbmt.2014.06.036. View

14.

Schuster S, Bishop M, Tam C, Waller E, Borchmann P, McGuirk J . Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma. N Engl J Med. 2018; 380(1):45-56. DOI: 10.1056/NEJMoa1804980. View

15.

Shah N, Ahn K, Litovich C, He Y, Sauter C, Fenske T . Is autologous transplant in relapsed DLBCL patients achieving only a PET+ PR appropriate in the CAR T-cell era?. Blood. 2020; 137(10):1416-1423. PMC: 7955408. DOI: 10.1182/blood.2020007939. View